What Happened?
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) jumped 3.8% in the morning session after several analyst firms raised their price targets following its acquisition of Vega Therapeutics.
H.C. Wainwright increased its price target on Incyte to $140 from $130, noting the acquisition was a key move to address the future loss of exclusivity for its drug, Jakafi. Other firms also viewed the deal favorably. Oppenheimer lifted its price target to $107, and Stifel reiterated its Buy rating with a $123 price target. The acquisition adds VGA039, a new antibody-based treatment for von Willebrand disease, to Incyte's product pipeline.
After the initial pop, the shares cooled down to $107.05, up 3.7% from the previous close.
Is now the time to buy Incyte? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Incyte’s shares are not very volatile and have only had 9 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 11 months ago when the stock gained 10.4% on the news that the company reported second-quarter financial results that beat analyst expectations and raised its full-year guidance for its top-selling drug, Jakafi.
The specialty drugmaker posted quarterly revenue of $1.22 billion, a significant 17.3% increase from the previous year, which surpassed the consensus estimate of $1.15 billion. Its adjusted profit of $1.57 per share also came in ahead of Wall Street's forecasts. The strong performance was driven by robust product sales, with revenue from its flagship drug Jakafi growing by 8% and sales of its Opzelura cream surging 35% year-over-year. Citing continued demand, Incyte lifted its 2025 sales forecast for Jakafi to a new range of $3.0 billion to $3.05 billion.
Incyte is up 5.5% since the beginning of the year, and at $107.05 per share, it is trading close to its 52-week high of $110.57 from January 2026. Investors who bought $1,000 worth of Incyte’s shares 5 years ago would now be looking at an investment worth $1,223.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.